×

Research and Markets: HIV-1 Infection - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/lstd9t/hiv1_infection) has announced the addition of Global Markets Direct's new report "HIV-1 Infection - Pipeline Review, H2 2012" to their offering.

This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection.

Scope

  • A snapshot of the global therapeutic scenario for HIV-1 Infection.
  • A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of HIV-1 Infection therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/lstd9t/hiv1_infection

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets